A St. Louis, Missouri medical device company is raising money in preparation for clinical trials of its pain-free cardioversion therapy for atrial fibrillation, developed by a former Case Western ...

(HealthDay News) — A delay to cardioversion of ≥12 hours from onset of acute atrial fibrillation symptoms is associated with a greater risk of thromboembolic complications, according to a research ...

Key points A 68-year-old woman from rural Ontario arrived at her local emergency department with worsening palpitations. Her medical history included breast cancer treated with surgical resection and ...

Apixaban lowers the risk of stroke compared to warfarin in anticoagulation-naïve patients with atrial fibrillation scheduled for elective cardioversion, according to new research. Apixaban lowers the ...

A team of Ochsner Health cardiologists recently published an article in the Journal of the American Medical Association (JAMA) Cardiology comparing two treatment strategies for patients with atrial ...

Pharmacologic cardioversion followed by electrical cardioversion and electrical cardioversion only were found to be safe and effective in patients presenting to the emergency department with recent ...

VANCOUVER, Feb. 13, 2014 /PRNewswire/ - Cardiome Pharma Corp. (NASDAQ: CRME) (TSX: COM) today announced that a poster titled "Medical conversion with Vernakalant on postoperative cardio-surgical ...

Clinical trial finds edoxaban to be equally effective as current use of warfarin. Clinical trial finds edoxaban to be equally effective as current use of warfarin. The results of the largest known ...

Please provide your email address to receive an email when new articles are posted on . Atrial fibrillation is extraordinarily common, and I see it an insane number of times. I have organized a set ...

A Food and Drug Administration (FDA) advisory committee has voted 11 to 2 against a recommendation that the agency approve a long-studied antiarrhythmic agent for cardioversion of recent-onset atrial ...